Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer
2016-002311-18Phase 3Terminated
- Sponsor
- Servier
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trifluridine + tipiracil in metastatic colon cancer (mCRC), sponsored by Servier. Primary endpoint: Safety and tolerability. Started Jul 2016; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2016-002311-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002311-18.